Literature DB >> 20400293

Risk of third malignancies and death after a second malignancy in retinoblastoma survivors.

T Marees1, F E van Leeuwen, M Schaapveld, S M Imhof, M R de Boer, W A Kors, P J Ringens, A C Moll.   

Abstract

Retinoblastoma patients have a strongly increased risk of second malignancies, and survivors with a third or subsequent malignancy are increasingly observed. However, it has not been examined whether survivors who developed a second malignancy have a greater risk of a subsequent malignancy. On the basis of the Dutch retinoblastoma registry, the risk of a third malignancy was compared with cancer risk in the Dutch population. Cox model analysis with a time-dependent covariate was used to compare the subsequent malignancy risk and survival among patients with and without a second malignancy. Risk of a third malignancy was increased 8-fold compared with the general population. The hazard ratio (HR) of a third malignancy after a second malignancy was more than 7-fold increased compared to the risk of a second malignancy after retinoblastoma. Radiotherapy increased the risk 3-fold. A third malignancy was associated with worse survival compared with survival of patients only diagnosed with a second malignancy (HR=5.0). Survivors of retinoblastoma who already developed a second primary malignancy have an even higher risk of subsequent primary malignancies than retinoblastoma survivors without a second malignancy. Treating physicians and patients should be aware of this higher risk. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20400293     DOI: 10.1016/j.ejca.2010.03.029

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  6 in total

1.  Impact of enucleation on adult retinoblastoma survivors' quality of life: A qualitative study of survivors' perspectives.

Authors:  Smita C Banerjee; Elaine Pottenger; Mary Petriccione; Joanne F Chou; Jennifer S Ford; Charles A Sklar; Leslie L Robison; Ruth A Kleinerman; Kevin C Oeffinger; Jasmine H Francis; David H Abramson; Ira J Dunkel; Danielle Novetsky Friedman
Journal:  Palliat Support Care       Date:  2020-06

2.  Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy.

Authors:  Jeannette R Wong; Lindsay M Morton; Margaret A Tucker; David H Abramson; Johanna M Seddon; Joshua N Sampson; Ruth A Kleinerman
Journal:  J Clin Oncol       Date:  2014-09-02       Impact factor: 44.544

3.  Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma (ARET0331): A report from the Children's Oncology Group.

Authors:  Debra L Friedman; Mark Krailo; Doojduen Villaluna; Dan Gombos; Bryan Langholz; Rima Jubran; Carol Shields; Linn Murphree; Joan O'Brien; Sandra Kessel; Carlos Rodriguez-Galindo; Murali Chintagumpala; Anna T Meadows
Journal:  Pediatr Blood Cancer       Date:  2016-12-26       Impact factor: 3.167

Review 4.  Establishment of an Orthotopic Xenograft Mice Model of Retinoblastoma Suitable for Preclinical Testing.

Authors:  Nathalie Cassoux; Aurélie Thuleau; Franck Assayag; Isabelle Aerts; Didier Decaudin
Journal:  Ocul Oncol Pathol       Date:  2015-04-09

5.  Variation of second cancer risk by family history of retinoblastoma among long-term survivors.

Authors:  Ruth A Kleinerman; Chu-Ling Yu; Mark P Little; Yi Li; David Abramson; Johanna Seddon; Margaret A Tucker
Journal:  J Clin Oncol       Date:  2012-02-21       Impact factor: 44.544

6.  Guidelines for imaging retinoblastoma: imaging principles and MRI standardization.

Authors:  Pim de Graaf; Sophia Göricke; Firazia Rodjan; Paolo Galluzzi; Philippe Maeder; Jonas A Castelijns; Hervé J Brisse
Journal:  Pediatr Radiol       Date:  2011-08-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.